Home | Biosimilars set the stage
In this issue
Contents
CSafeAPS
Mimotopes Company Insight
Briefing
Industry news
The pharma industry briefing
Tripletree
Comment
Cannabinoids receptors: popular preclinical target but banned in 137 countries
Ozempic compensating for Wegovy’s supply shortage due to high demand
Manufacturing challenges set back progress of cell therapies in oncology
Chinese transition to innovative pharma needs more investment
DLBCL: a rapidly evolving treatment landscape with a crowded pipeline
Bio Image Systems Inc.
In Depth
Humira biosimilars set the stage for long-awaited 2023 US launches
Expanding ketamine’s horizons for rare neurological disorders
The “Medical Bypass”: New drugs to strike obesity
Running low on comparators: drug shortages in oncology clinical trials
ACT EU state of play: EMA’s headway to transform clinical trials
CMO Moves: Regulatory catalysts for drug manufacturing-December
Events
Next issue
12/14/2022 00:00:00
Go to article:
Home | Biosimilars set the stage
Go to article:
In this issue
Go to article:
Contents
Go to article:
CSafeAPS
Go to article:
Mimotopes Company Insight
Go to article:
Briefing
Go to article:
Industry news
Go to article:
The pharma industry briefing
Go to article:
Tripletree
Go to article:
Comment
Go to article:
Cannabinoids receptors: popular preclinical target but banned in 137 countries
Go to article:
Ozempic compensating for Wegovy’s supply shortage due to high demand
Go to article:
Manufacturing challenges set back progress of cell therapies in oncology
Go to article:
Chinese transition to innovative pharma needs more investment
Go to article:
DLBCL: a rapidly evolving treatment landscape with a crowded pipeline
Go to article:
Bio Image Systems Inc.
Go to article:
In Depth
Go to article:
Humira biosimilars set the stage for long-awaited 2023 US launches
Go to article:
Expanding ketamine’s horizons for rare neurological disorders
Go to article:
The “Medical Bypass”: New drugs to strike obesity
Go to article:
Running low on comparators: drug shortages in oncology clinical trials
Go to article:
ACT EU state of play: EMA’s headway to transform clinical trials
Go to article:
CMO Moves: Regulatory catalysts for drug manufacturing-December
Go to article:
Events
Go to article:
Next issue